Grace Therapeutics raises $10M in private placement; extends cash runway to end of 2028

Grace Therapeutics, Inc.

Issued 4,761,904 shares at $2.10/share for gross proceeds of $10M; closed August 6, 2026.
Net proceeds plus existing cash expected to extend cash runway to end of calendar 2028.
Dual-source manufacturing strategy for GTx-104 initiated; NDA resubmission timing depends on manufacturing readiness.
Technology transfer to a U.S.-based contract manufacturer is underway.
Craig-Hallum acted as sole placement agent for the private placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.